Our Pipeline

Utilizing Our Proprietary Technologies to Create Life-Changing Therapies

Internal Development Programs

Program Indication Preclinical IND Enabling Phase 1 Phase 2 Highlights
SYSTEMIC DNASE I + ICIs Solid Tumors
Preclinical Phase complete
IND Enabling Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Planned First-in-Human Study to Evaluate DNase Combined with Immune Checkpoint Inhibitors or Chemotherapy
SYSTEMIC DNASE I + CAR T Solid Tumors
Preclinical Phase in progress
IND Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Potential to enhance CAR T cell function in the tumor microenvironment
DNASE-ARMORED CAR T Solid Tumors
Preclinical Phase in progress
IND Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Potential to enhance CAR T cell function in the tumor microenvironment
XCART™ PLATFORM B-Cell Non-Hodgkin Lymphoma
Preclinical Phase in progress
IND Enabling Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
Patient and tumor-specific cell therapy approach

Receiving royalties on net sales through license agreement in the field of coagulation disorders

Program Indication Partners
POLYXEN® Next Generation Half-Life Extension Platform Technology Undisclosed Receiving royalties on net sales through exclusive license agreement in the field of coagulation disorders
EREPOXEN (PSA-EPO) Treatment of anemia in patients with chronic kidney disease (CKD) Partner filed registration dossier in Russia